Why Barinthus Biotherapeutics plc’s (BRNS) Stock Is Down 5.47%
As of Monday, November 03, Barinthus Biotherapeutics plc’s BRNS share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.
Commentary & Analysis
Why Barinthus Biotherapeutics plc’s (BRNS) Stock Is Up 5.43%
As of Friday, October 31, Barinthus Biotherapeutics plc’s BRNS share price has surged by 5.43%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Barinthus Biotherapeutics plc’s (BRNS) Stock Is Down 6.98%
As of Friday, October 24, Barinthus Biotherapeutics plc’s BRNS share price has dipped by 6.98%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Barinthus Biotherapeutics plc’s (BRNS) Stock Is Down 7.19%
As of Wednesday, October 22, Barinthus Biotherapeutics plc’s BRNS share price has dipped by 7.19%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Barinthus Biotherapeutics plc’s (BRNS) Stock Is Up 6.61%
As of Monday, October 20, Barinthus Biotherapeutics plc’s BRNS share price has surged by 6.61%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | BRNS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $22.8 | $252.6 | 11% |
|
| Shares Out (Mil) | 40.8 | 52.3 | 43% |
|
| Institutional Ownership | 72.6% | 92.1% | 44% |
|
| Float (Mil) | 27.3 | 40.2 | 34% |
|
| Beta | -0.40 | 0.95 | 2% |
|
| Avg Daily Volume (000s) | 26 | 455 | 23% |
|
| Price Change (52-week) |
(63.5%) | 52.9% | 11% |
|
| Growth | BRNS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (30.3%) | (9.9%) | 13% |
|
| EPS (5yr) | 6.0% | 16.0% | 39 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (17.6%) | (15.6%) | 39% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.280) | ($1.150) | ($1.150) | |
| Month Ago EPS | ($0.280) | ($1.150) | ($1.150) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.280) | ($1.150) | ($1.150) | |
| Year/Year Chg | 100.0% | (29.9%) | na | |
| Financials | BRNS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($52) | ($43) | 16% |
|
| EPS (TTM) | ($1.286) | ($1.600) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($36) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $9 | $5 | 28% |
|
| Enterprise Value (Q1) (Mil) | ($30) | $180 | 1% |
|
| Valuation | BRNS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.34 | 2.56 | 5% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | BRNS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (44.7%) | (49.8%) | 13% |
|
| ROE | (57.5%) | (55.5%) | 14% |
|
| Liabilities to Assets | 27.9% | 30.3% | 19% |
|
| F-Score | 1 | 3 | 1% |
|
Barinthus Biotherapeutics plc did not pass any screens on 7/31/2026.
